These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31473879)

  • 1. Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis.
    de Carvalho Jennings Pereira WL; Flauzino T; Alfieri DF; Oliveira SR; Kallaur AP; Simão ANC; Lozovoy MAB; Kaimen-Maciel DR; Maes M; Reiche EMV
    Neuromolecular Med; 2020 Mar; 22(1):73-80. PubMed ID: 31473879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
    Thouvenot E; Orsini M; Daures JP; Camu W
    Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prolactin level in patients with relapsing-remitting multiple sclerosis during relapse.
    Moshirzadeh S; Ghareghozli K; Harandi AA; Pakdaman H
    J Clin Neurosci; 2012 Apr; 19(4):622-3. PubMed ID: 22341909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-inflammatory, metabolic and hormonal biomarkers are associated with the clinical forms and disability progression in patients with multiple sclerosis: A follow-up study.
    de Carvalho Jennings Pereira WL; Flauzino T; Alfieri DF; Oliveira SR; Kallaur AP; Simão ANC; Lozovoy MAB; Kaimen-Maciel DR; Maes M; Reiche EMV
    J Neurol Sci; 2020 Mar; 410():116630. PubMed ID: 31887671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
    Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
    Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
    Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.
    Oliveira SR; Kallaur AP; Reiche EMV; Kaimen-Maciel DR; Panis C; Lozovoy MAB; Morimoto HK; Maes M; Dichi I; Simão ANC
    Mol Neurobiol; 2017 May; 54(4):2961-2968. PubMed ID: 27026183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor alpha (TNF-α) and its soluble receptors are associated with disability, disability progression and clinical forms of multiple sclerosis.
    Ribeiro CM; Oliveira SR; Alfieri DF; Flauzino T; Kaimen-Maciel DR; Simão ANC; Maes M; Reiche EMV
    Inflamm Res; 2019 Dec; 68(12):1049-1059. PubMed ID: 31559449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum orexin-A levels are associated with disease progression and motor impairment in multiple sclerosis.
    Gencer M; Akbayır E; Şen M; Arsoy E; Yılmaz V; Bulut N; Tüzün E; Türkoğlu R
    Neurol Sci; 2019 May; 40(5):1067-1070. PubMed ID: 30645749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum prolactin level in patients with multiple sclerosis: a case control study.
    Harirchian MH; Sahraian MA; Shirani A
    Med Sci Monit; 2006 Apr; 12(4):CR177-80. PubMed ID: 16572053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in correlates of fatigue between relapsing and progressive forms of multiple sclerosis.
    Herring TE; Alschuler KN; Knowles LM; Phillips KM; Morean WM; Turner AP; Ehde DM
    Mult Scler Relat Disord; 2021 Sep; 54():103109. PubMed ID: 34237561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between LincR-Gng2-5'and LincR-Epas1-3'as with the severity of multiple sclerosis in Egyptian patients.
    Shaker OG; Golam RM; Ayoub S; Daker LI; Elguaad MKA; Said ES; Khalil MAF
    Int J Neurosci; 2020 May; 130(5):515-521. PubMed ID: 31790618
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of Demographic and Clinical Factors in Cognitive Functioning of Persons with Relapsing-Remitting and Progressive Multiple Sclerosis.
    Costa SL; DeLuca J; Sandroff BM; Goverover Y; Chiaravalloti ND
    J Int Neuropsychol Soc; 2018 Feb; 24(2):139-146. PubMed ID: 28830576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients.
    Sfagos C; Makis AC; Chaidos A; Hatzimichael EC; Dalamaga A; Kosma K; Bourantas KL
    Mult Scler; 2005 Jun; 11(3):272-5. PubMed ID: 15957506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process.
    Zhang Y; Taylor BV; Simpson S; Blizzard L; van der Mei I
    Eur J Neurol; 2019 Jan; 26(1):155-161. PubMed ID: 30133059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased MMP-9 production in primary progressive multiple sclerosis patients.
    Sastre-Garriga J; Comabella M; Brieva L; Rovira A; Tintoré M; Montalban X
    Mult Scler; 2004 Aug; 10(4):376-80. PubMed ID: 15327032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.
    Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV
    Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament Light Chain Serum Levels Mirror Age and Disability in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Study.
    Husseini L; Jung J; Boess N; Kruse N; Nessler S; Stadelmann C; Metz I; Haupts M; Weber MS
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200279. PubMed ID: 38991171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Walking capacity and ability are more impaired in progressive compared to relapsing type of multiple sclerosis.
    Feys P; Bibby BM; Baert I; Dalgas U
    Eur J Phys Rehabil Med; 2015 Apr; 51(2):207-10. PubMed ID: 25180640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis.
    Wilczak N; Ramsaransing GS; Mostert J; Chesik D; De Keyser J
    Mult Scler; 2005 Feb; 11(1):13-5. PubMed ID: 15732261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.